DSM BioSolutions has entered into an agreement with Laboratoires Mayoly Spindler, Chatou Cedex, France, for the manufacture of ‘MS1819’ lipase. DSM has successfully completed process development and commenced
Santarus has received the $20m milestone payment previously announced on December 1, 2009 relating to the approval of Zegerid OTC (omeprazole 20mg/sodium bicarbonate 1100mg capsules) under its over-the-counter
PGxHealth, a division of Clinical Data, has entered into a research collaboration with Deutsches Herzzentrum (DHZ) to evaluate the predictive value of genetic markers, including PGxHealth proprietary markers,
Lundbeck and to-BBB are entering into a research collaboration to evaluate delivery of antibodies to the brain for Central Nervous System (CNS) diseases. Reportedly, the research could provide
AdvanDx has received FDA 510(k) clearance for a fast, 90 minutes protocol for its E. coli/P. aeruginosa PNA FISH and EK/P. aeruginosa PNA FISH tests. The faster protocol
Prasco Laboratories (Prasco) has signed a distribution and supply agreement with Stiefel Laboratories (Stiefel), a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco’s line
Mylan has reported that its subsidiary, Matrix Laboratories (Matrix) has received tentative approval from the FDA under the President’s Emergency Plan for AIDS Relief (PEPFAR), for its New
Ablynx has presented results from the open label extension of the phase Ib study of its anti-thrombotic, ALX-0081, in patients with stable angina undergoing percutaneous coronary intervention (PCI).
Shire has submitted a Biologics License Application (BLA) to the FDA for Replagal (agalsidase alfa), its enzyme replacement therapy for Fabry disease. Replagal first received marketing authorisation in
AVI BioPharma has presented initial efficacy data from the ongoing phase 1b/2 clinical trial of AVI-4658 for the systemic treatment of patients with Duchenne muscular dystrophy (DMD). Patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.